Biosciences
Public-Private Collaboration Aims to Find a New Treatment for Pancreatic Cancer
At the HudsonAlpha Institute for Biotechnology, casual gatherings can lead to incredible research opportunities. A fortuitous encounter…
Other Post
-
The Bioscience Bioeconomy Bonanza
January 16, 2021 -
Southeast Biotech Campus Fuels Entrepreneurs and Growing Ventures Labs for Lease in Increments Startups Can Afford in a Community of Biotechs
November 19, 2019 -
Biotech and Pharmaceutical Industry
November 18, 2019 -
Embraced by More States as an Economic Engine
April 05, 2018
Considering Data Demand
Nonstop data demands accelerating growth of both large and small data centers
By David Hodes
As new advancements are made in the rapidly expanding cloud computing industry, companies are seeking to establish data centers in areas that are able to support and promote the enormous amount of computing power that…
Bringing Work to Life
Life Sciences and Biotech Gain Momentum
By Mark Kleszczewski
While not immune to lingering fallout from the 2008-09 economic crisis, the bioscience industry has weathered difficult times better than most industries and is on course to regain its previous high employment levels, according to the Biotechnology Innovation Association (BIO…
Breathing Life Back Into Bioscience
Caption: 3737 Market Street is the newest building on the University City Science Center’s campus, located in Philadelphia. Spark Therapeutics is one of the building’s residents, taking up an entire floor. Photo: CJ Dawson/Courtesy of the University City Science Center
By Mark Kleszczewski
Innovations blur the edges…
Bioscience’s Bright Spots
By Mark Kleszczewski
Collaboration within clusters trumps competition.
Despite high failure rates, difficulties in obtaining early-stage funding and rapidly-changing market dynamics, the U.S. bioscience and biopharma industries not only weathered the recession, but actually added jobs while other knowledge-based industries lost traction.
While well-established industry…
What’s in Store for Biopharma?
By Rachel Duran
For the biopharma industry, the so-called valley of death is where discoveries get stuck, unable to cross the valley and eventually become part of the biopharma pipeline. With a stagnant venture capital climate, the industry has become severely strained and pharmas are going out of business…